• All
  • News
  • Press Releases

Don Webber’s CEO Perspective #4 June 2024

To the Organ Transplantation Community, We are just wrapping up the trifecta of Spring 2024 national and global congresses for the transplantation community: the European Liver and Intestine Transplant Association (ELITA) Summit 2024, organized by European Society for Organ Transplantation (ESOT) in April; the 2024 Annual Congress of the International…

Latest Results from End-Ischemic HOPE U.S. Randomized Clinical Trial for Liver Transplantation Show Safety, Reduced Early Allograft Dysfunction, and Shorter Hospital Stays with HOPE

Chicago, June 4, 2024 – Bridge to Life Ltd, a leading provider of organ preservation solutions, has announced the latest findings from the Bridge to HOPE clinical trial, utilizing the VitaSmart Machine Perfusion System. The trial evaluates the safety and efficacy of static cold storage (SCS), the current standard for ex-vivo organ preservation, compared to SCS followed by hypothermic…

Bridge to Life Announces Late-Breaker, Oral and Poster Presentations on Bridge to HOPE trial with VitaSmart at 2024 American Transplant Congress (ATC) in Philadelphia, PA, June 1-5, 2024

Chicago, May 8, 2024   Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced acceptance of four abstracts based on data from its U.S. pivotal clinical trial on HOPE using the VitaSmart Liver Machine, including a late-breaker, for presentation at the 2024 annual meeting of the American Transplant Congress (ATC). The conference is scheduled to take place in Philadelphia, PA from June 1-5, 2024…

Meta-Analysis of Data from Trials of Machine Perfusion Technologies in Liver Transplantation Demonstrates Clinical Advantages of Hypothermic Oxygenated Machine Perfusion (HOPE), according to Bridge to Life Ltd.

Results of late-breaker Cochrane review and meta-analysis confirmed significant improvement in several parameters with HOPE compared to static cold storage and normothermic machine perfusion (NMP). While both technologies proved to be superior to SCS, there is no good evidence that NMP has the same benefits over SCS in terms of these clinically relevant…

Don Webber’s CEO Perspective #3

To the Organ Transplantation Community, In my last post , I referenced that through hypothermic oxygenated perfusion (HOPE), organs awaiting transplantation are cooled to temperatures typically ranging between 4 and 10°C, significantly reducing their metabolic rate to about 10% of normal. This oxygen-rich perfusion revitalizes the mitochondria, the powerhouse and energy reservoir of the cells. Essentially, this process primes the cells before transplantation…

Two Independent Studies Representing Largest Real-World Experience with Hypothermic Oxygenated Machine Perfusion (HOPE) Reinforce Significant Benefits in Liver Preservation Before Transplantation, according to Bridge to Life Ltd.

Portuguese study confirms use of HOPE provides demonstrably improved liver graft utilization with reduced rates of non-anastomatic biliary stricture (NAS); Italian study demonstrates increasing experience in managing DCD (donation after circulatory determination of death) results in greater utilization of more marginal donors and transplantation in…

Don Webber’s CEO Perspective #2

To the Organ Transplantation Community,
As April unfolds, National Donate Life Month comes into focus, illuminating the urgent importance of organ, eye, and tissue donation. This dedicated month honors the incredible donors and their families whose selflessness transforms lives through organ transplants. An outcome of this awareness is the increased media attention on transplantation…

Bridge to Life Announces Abstract Presentations at The 2024 International Congress of the International Liver Transplantation Society (ILTS) in Houston, Texas, May 1-4, 2024

Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation. The conference is scheduled to take place in Madrid, Spain, from April 18-20, 2024. Abstracts to be presented: 100 Hypothermic Oxygenated Perfusion liver transplants in a Portuguese Centre, Júlio Constantino, MD et a…

Bridge to Life Announces Abstract Presentations at The European Society for Transplantation’s ELITA Summit 2024 in Madrid, Spain, April 18-20, 2024

Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation. The conference is scheduled to take place in Madrid, Spain, from April 18-20, 2024. Abstracts to be presented: 100 Hypothermic Oxygenated Perfusion liver transplants in a Portuguese Centre, Júlio Constantino, MD et a…

CEO Don Webber will now be offering his insights with his own perspective posts

To the Organ Transplantation Community,
In keeping with the Bridge to Life mission and philosophy of offering premier organ transplantation products with a strong focus on product quality, innovation and accessibility in partnership with leading Transplant Centers and Organ Procurement Organizations (OPO) globally, I am excited to introduce here a periodic blog where I will update our community on Bridge to Life…

Bridge to Life Reintroduces EasiSlush® to the US Market, Meeting High Demand for Easy-to-Use Sterile Slush for Organ Transplantation

Bridge to Life Ltd, a leading provider of organ preservation solutions, today announces the return of EasiSlush ™ to the US market, effective immediately. With its unmatched ease of use, high quality and portability, EasiSlush has become the preferred choice for organ transplant professionals who are responsible for transporting life-giving organs from donors to recipients under critical timelines.

Bridge to Life Achieves ISO 13485:2016 Certification, Reinforcing Commitment to Quality and Safety in Hypothermic Oxygenated Perfusion and Cold Flush Organ Preservation Solutions

Bridge to Life Ltd, a renowned market leader in cold flush organ preservation solutions, is proud to announce its recent certification for ISO 13485:2016. This achievement further solidifies the company’s commitment to maintaining exceptional standards of quality and safety in its premier products, including Belzer UW, EasiSlush® and VitaSmart™ Machine Perfusion System (Europe).

Bridge to Life Divests Certain Assets to TransMedics

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle heart perfusion assets.

ADVANCING TRANSPLANTATION TECHNOLOGIES: Bridge to HOPE Trial Demonstrates Promising Findings with Hypothermic Oxygenated Perfusion

Bridge to Life Ltd. announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).

Early Closure of Bridge to Life Ltd. HOPE Liver Trial Enrollment Affirms the Potential of Hypothermic Oxygenated Perfusion

Bridge to Life, Ltd. announced that it met positive criteria from interim analysis for early enrollment closure of its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Bridge to Life Ltd. Names New Chief Financial Officer and Vice-President of Operations

Bridge to Life, Ltd. announced the expansion of their executive leadership team by appointing Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations.

Bridge to Life Ltd. Announces Early Results from its Pivotal Bridge to HOPE Liver Clinical Trial

Bridge to Life, Ltd. announced early results from its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Bridge to Life Ltd. Names Don Webber as President and CEO

Steve Schweighardt, founder and former CEO to retire from daily operations but will remain as Chairman of the Board.

Bridge to Life Ltd. Receives Breakthrough Device Designation from the FDA

Bridge to Life advances their perfusion system development with the breakthrough device designation for the LifeCradle® Heart Preservation Transport system.

Bridge to Life Ltd. Announces First Enrollment and Orthotopic Liver Transplantation in its Pivotal Bridge to HOPE Liver Clinical Trial

Bridge to Life Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced first enrollment and orthotopic liver transplantation in its U.S. pivotal Bridge to HOPE Liver Clinical Trial.

Bridge to Life Ltd. Receives Investigational Device Exemption Approval from the FDA

The primary endpoint for the trial is the rate of early allograft dysfunction between treatment groups; additional key endpoints include rates of ischemic cholangiopathy and patient and graft survival up to 1-year post-transplantation. 

Bridge to Life Announces First Close of $56 Million Growth Financing Led by Perceptive Advisors

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by Perceptive Advisors, a leading life sciences investment firm.

Bridge to Life CEO Stevan Schweighardt Featured in CEOCFO Magazine

Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life’s current and upcoming solutions to make organ transplantations more successful.

Bridge to Life and Tevosol Merge to Commercialize Portable Normothermic Machine Preservation Technology Platform for Organ Transplantation

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life’s significant financial commitment to manufacture, trial, and launch Tevosol’s portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform.

Watch ILTS Insights Webinar Series Sponsored by BTL

Bridge to Life is proud to have sponsored two webinars in the ILTS Insights series. Each webinar can be watched below.